Prescription Required
Formulation: Tablet
(Brand Option)
Select the prescribed dosage
Select the quantity to see the price.
Prescription Required
Formulation: Tablet
Select the quantity to see the price.
* This price includes a dispensing fee, medical review fee, and packing fee.
Shipped and delivered directly to your doorstep
Promacta contains the active ingredient eltrombopag. It is a prescription medication used to increase blood cell production in people with certain blood disorders.
Promacta is mainly used when the body does not have enough platelets. Platelets are small blood cells that help form clots and stop bleeding after an injury.
When your platelet count is very low, you may experience easy bruising, frequent nosebleeds, bleeding gums, small red or purple spots under the skin, or bleeding that takes longer than usual to stop. A severely low platelet count may also increase the risk of serious internal bleeding.
Promacta may be prescribed to adults and children aged 1 year and older with persistent or chronic immune thrombocytopenia, also called ITP.
ITP is an immune disorder in which the immune system mistakenly attacks and destroys platelets. The body may also have difficulty producing enough new platelets to replace those that are lost.
Promacta is generally considered when other ITP treatments have not worked well enough. These treatments may include corticosteroids, immunoglobulins, or surgery to remove the spleen.
Promacta should generally be used only when the low platelet count and the patient’s overall condition create an increased risk of bleeding. The goal is to raise the platelet count to a safer level—not necessarily to bring it completely into the normal range.
By encouraging the bone marrow to produce more platelets, Promacta may reduce the risk of bleeding and make everyday activities safer.
As the platelet count improves, your healthcare provider may also be able to reduce or stop certain other ITP treatments. However, this should only be done under medical supervision.
Promacta does not cure ITP. Platelet counts may decrease again after treatment is stopped, so regular blood tests are needed during treatment and for a period after discontinuation.
Promacta may also be used to treat severe aplastic anemia, a serious condition in which the bone marrow does not produce enough blood cells.
The bone marrow is the soft tissue inside certain bones where red blood cells, white blood cells, and platelets are produced. In severe aplastic anemia, the bone marrow may not make enough of any of these cell types.
Low red blood cell levels can cause tiredness, weakness, dizziness, or shortness of breath. Low white blood cell levels can increase the risk of infections. Low platelet levels can increase bruising and bleeding.
Promacta may be used in two main ways for severe aplastic anemia:
In some patients, Promacta may stimulate the bone marrow to produce more than just platelets. It may also help increase red and white blood cell counts.
Promacta may be prescribed to certain people with chronic hepatitis C who have platelet counts that are too low to begin or continue interferon-based antiviral treatment.
Interferon therapy can lower platelet counts further. Promacta may increase the platelet count enough to allow treatment to begin or continue.
Interferon-based treatment is now used less frequently because newer antiviral medicines are available. However, this remains an approved use in selected patients whose low platelet count prevents or limits interferon-based therapy.
Promacta belongs to a group of medications called thrombopoietin receptor agonists.
Thrombopoietin is a natural hormone that helps control platelet production. It sends signals to immature cells in the bone marrow, encouraging them to develop into cells called megakaryocytes. Megakaryocytes then release platelets into the bloodstream.
Promacta attaches to and activates the thrombopoietin receptor. This stimulates the bone marrow to produce more platelets.
Promacta does not replace platelets directly. Instead, it encourages your body to make more of its own platelets over time.
Platelet counts may begin to increase within one to two weeks after starting Promacta, although the response varies between patients.
You will not usually feel the platelet count increasing. Blood tests are required to determine whether the medication is working and whether the dose needs to be changed.
Your healthcare provider will aim for a platelet count that reduces your risk of bleeding. Raising the count too high can increase the risk of blood clots, so the dose must be adjusted carefully.
Regular blood tests are an essential part of Promacta treatment. Your healthcare provider may monitor:
Blood tests may be performed frequently when treatment begins or when the dose changes. Once your blood counts become stable, testing may be needed less often.
Promacta is not intended to make platelet counts completely normal. It should be used to reach and maintain the lowest platelet count needed to reduce the risk of bleeding.
Promacta is also not approved to treat myelodysplastic syndromes. In patients with these disorders, treatment may be associated with serious risks.
Take Promacta exactly as prescribed and attend all scheduled blood tests and follow-up appointments. Contact your healthcare provider promptly if you develop unusual bleeding, severe bruising, yellowing of the skin or eyes, dark urine, severe abdominal pain, chest pain, shortness of breath, or pain and swelling in one leg.
Promacta is usually taken by mouth once a day. Take it exactly as prescribed by your healthcare provider.
You may take Promacta without food or with a meal that contains no more than 50 mg of calcium. Low-calcium meals do not significantly affect how much medication your body absorbs.
Calcium, iron, magnesium, aluminum, selenium, and zinc can attach to Promacta in the digestive tract and prevent your body from absorbing it properly. Take Promacta at least:
This includes dairy products, calcium-fortified foods and drinks, antacids, multivitamins, and mineral supplements.
Swallow the tablet whole with water. Do not split, crush, chew, or dissolve it. Do not mix the tablet into food or liquid.
Promacta is also available as a powder for oral suspension. The powder follows different preparation instructions and should be mixed only with water as directed. Do not use hot water.
For most adults and children aged 6 years and older with persistent or chronic immune thrombocytopenia, the usual starting dose is 50 mg once daily.
Children aged 1 to 5 years usually start with 25 mg once daily. Some patients may need a lower starting dose, including those with liver impairment and certain patients of East or Southeast Asian ancestry.
Your healthcare provider will adjust your dose based on regular platelet counts. The dose may be increased or reduced in 25 mg steps, generally after waiting at least two weeks to assess the effect of a dose change. The maximum recommended dose for immune thrombocytopenia is 75 mg once daily.
The goal is not to make your platelet count completely normal. Your healthcare provider will use the lowest dose needed to maintain a platelet count that reduces your risk of bleeding.
The dosage for severe aplastic anemia depends on whether Promacta is being used as part of the first treatment plan or after previous treatment has not worked.
When Promacta is used with antithymocyte globulin and cyclosporine as an initial treatment, the usual starting dose for patients aged 12 years and older is 150 mg once daily. Lower age-based doses are used for younger children, and reduced doses may be needed for patients of East or Southeast Asian ancestry or those with liver impairment. Treatment may continue for up to six months as part of the prescribed combination regimen.
For severe aplastic anemia that has not responded adequately to immunosuppressive therapy, the usual starting dose is generally 50 mg once daily. The dose may be increased gradually according to blood counts and treatment response, up to a maximum of 150 mg once daily.
Therefore, 150 mg once daily for six months is not the correct starting regimen for every patient with severe aplastic anemia.
Your healthcare provider will order regular blood tests to monitor:
Do not change your dose based on your own platelet results. Raising the platelet count too much can increase the risk of blood clots.
Take Promacta at approximately the same time each day. Contact your healthcare provider or pharmacist if you are unsure about your dose, dietary restrictions, mineral supplements, or the timing of other medications.
Promacta (Eltrombopag Olamine) is available in the following forms and strength:
Tell your healthcare provider if you are pregnant, think you may be pregnant, or plan to become pregnant. There is limited information about Promacta use during pregnancy, and animal studies suggest that it may harm an unborn baby.
Promacta should generally be used during pregnancy only when your healthcare provider determines that the expected benefits outweigh the possible risks.
If you could become pregnant, use an effective form of birth control while taking Promacta and for at least 7 days after your last dose. Contact your healthcare provider promptly if you become pregnant during treatment. Do not stop taking Promacta without medical advice.
Breastfeeding is not recommended while taking Promacta. It is not known whether eltrombopag passes into human breast milk, but the medication could potentially cause serious side effects in a nursing baby.
Speak with your healthcare provider about whether you should stop breastfeeding or use a different treatment.
Promacta helps your bone marrow produce more platelets, but it does not cure the underlying condition. Your platelet count may decrease again after treatment is stopped, which can increase your risk of bleeding.
Your healthcare provider will usually monitor your blood counts for several weeks after your last dose. Contact them if you develop unusual bruising, frequent nosebleeds, bleeding gums, blood in your urine or stool, or bleeding that does not stop.
Promacta is not approved to treat myelodysplastic syndromes, also called MDS. In studies involving people with MDS, eltrombopag was associated with an increased risk of disease progression to acute myeloid leukemia and an increased risk of death.
This warning does not mean that Promacta generally causes blood cancer in everyone who takes it for an approved condition. Your healthcare provider should confirm the cause of your low blood counts before starting treatment.
You do not have to take Promacta completely on an empty stomach. You may take it without food or with a meal that contains no more than 50 mg of calcium.
Calcium and certain other minerals can attach to Promacta in your digestive system and prevent your body from absorbing it properly. Take Promacta:
Products that may interfere with Promacta include dairy products, calcium-fortified juices, antacids, multivitamins, and supplements containing calcium, iron, magnesium, aluminum, selenium, or zinc.
You do not need to avoid dairy products throughout the entire day. You only need to separate them from your Promacta dose by the recommended amount of time.
Promacta can cause serious and potentially life-threatening liver injury. Your healthcare provider will order blood tests to check your liver before treatment begins and regularly while you are taking the medication.
These tests may measure liver enzymes and bilirubin. Depending on the results, your healthcare provider may repeat the tests more often, lower your dose, interrupt treatment, or stop Promacta.
Contact your healthcare provider immediately if you develop possible signs of a liver problem, including:
Do not wait for your next scheduled appointment if these symptoms occur.
In people with chronic hepatitis C, taking Promacta with interferon and ribavirin may increase the risk of hepatic decompensation. This means that an already damaged liver may become unable to perform its normal functions.
Patients receiving this combination require close monitoring. Tell your healthcare provider immediately if you develop increasing abdominal swelling, confusion, severe weakness, yellowing of the skin or eyes, dark urine, or other signs of worsening liver function.
Take Promacta exactly as prescribed and attend every scheduled blood test. Do not change your dose or stop treatment based on your own platelet or liver test results.
Seek immediate medical attention if you develop severe bleeding, chest pain, sudden shortness of breath, coughing up blood, sudden weakness on one side of your body, or pain and swelling in one leg. These may be signs of serious bleeding or a blood clot.
Yes. Promacta can interact with certain medications, mineral supplements, antacids, and foods. Products containing calcium, iron, magnesium, aluminum, zinc, or selenium can attach to Promacta in your digestive system and prevent your body from absorbing it properly. These may include antacids, multivitamins, mineral supplements, dairy products, and calcium-fortified foods or drinks. Take Promacta at least 2 hours before or at least 4 hours after these products. Promacta may also interact with certain cholesterol medications, including rosuvastatin, and some medications used to treat HIV or hepatitis C. Tell your healthcare provider and pharmacist about every prescription medication, nonprescription product, vitamin, mineral, and herbal supplement you take.
For people with immune thrombocytopenia, platelet counts often begin to increase within 1 to 2 weeks after starting Promacta. However, the response time can vary depending on the condition being treated, the dose, and the individual patient. You may not feel the platelet count increasing, so regular blood tests are needed to determine whether the medication is working. Your healthcare provider may adjust your dose based on your platelet count and response to treatment. Continue taking Promacta exactly as prescribed. Do not increase your dose or stop treatment based on your own blood-test results.
Promacta may be taken without food or with a meal that contains no more than 50 mg of calcium. Do not take it at the same time as dairy products, calcium-fortified foods or drinks, antacids, or mineral supplements containing calcium, iron, magnesium, aluminum, zinc, or selenium. Take Promacta at least 2 hours before or at least 4 hours after these foods and products. You do not need to avoid calcium-containing foods for the entire day; you only need to separate them from your dose.
Promacta may be used in some people with liver problems, but additional caution and monitoring are required. The medication can cause serious liver injury, and some patients with liver impairment may need a lower starting dose. Your healthcare provider will order liver-function blood tests before treatment and regularly while you are taking Promacta. Depending on the results, your dose may be reduced, temporarily interrupted, or stopped. Contact your healthcare provider promptly if you develop unusual tiredness, loss of appetite, nausea, pain in the upper-right side of your abdomen, dark urine, pale stools, confusion, or yellowing of your skin or eyes.
No. Promacta does not cure immune thrombocytopenia or other underlying conditions that cause low platelet counts. It stimulates the bone marrow to produce more platelets, helping raise the platelet count to a safer level and reduce the risk of bleeding. It is not intended to make the platelet count completely normal. Platelet levels may decrease again after treatment is stopped. Continue attending regular appointments and blood tests so your healthcare provider can monitor your condition and adjust your treatment safely.
| Generic name: | Eltrombopag Olamine |
|---|---|
| Formulation: | Tablet |
| Strength(s): | 25mg, 50mg |
| Quantities Available: | 14, 42 |
Our online Canadian Pharmacy is known for high standards of quality, safety, and efficiency when it comes to medications.
Our pharmacy offers lower prices on prescription drugs compared to traditional pharmacies.
Absolutely. You can purchase Promacta through Online Pharmacies Canada. A lot of customers purchase Promacta from our website to reduce the cost.
No, we do not sell eltrombopag olamine on our website. However, you can still enjoy low prices on Promacta, which contains eltrombopag olamine as an active ingredient. To purchase Promacta, you will need a valid prescription from your healthcare provider. We require this to dispense the medication. You can conveniently submit your prescription by mail, fax, or upload it through your online account to facilitate the ordering process.
When ordering Promacta (eltrombopag olamine) from a Canadian pharmacy, you can purchase up to a 90-day supply at one time.
Here’s what you need to know:
Dosage and Quantity: Promacta is commonly prescribed in dosages of 25 mg or 50 mg taken once daily. For a 90-day supply, you would order 90 tablets (90 days x 1 tablet per day).
Buying Promacta from a reputable Canadian pharmacy like Online Pharmacies Canada is considered safe. Online Pharmacies Canada is verified by the Canadian International Pharmacy Association (CIPA). CIPA-approved pharmacies are recognized as safe in the US.
We encourage you to read our pharmacy reviews from verified customers before making a purchase decision.
At Online Pharmacies Canada, the cost of Promacta is:
25mg Tablets:
50mg Tablets:
Yes, we ship Promacta to both the United States and Puerto Rico.
Watch how Online Pharmacies Canada is helping customers save money on their medications.
Online Pharmacies Canada has provided information from third parties intended to increase awareness and does not contain all the information about Promacta (Eltrombopag Olamine). Talk to your doctor or other qualified medical practitioners for medical attention or advice, or if you have any concerns about Promacta (Eltrombopag Olamine).
REVIEWS